|
FDA approves asthma aerosol developed by Acton Pharmaceuticals
Boston.com Marlborough-based Acton Pharmaceuticals announced Thursday that the Food and Drug Administration has approved its supplemental new drug application for Aerospan Inhalation Aerosol, an asthma treatment for patients 6 years of age and older. Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma |
View full post on asthma – Google News